Analyzing predictive models following definitive radiotherapy for prostate carcinoma

Cancer

Volumn 80, Issue 6, 1997, Pages 1093-1102

  Movsas, Benjamin ^a   Hanlon, Alexandra L ^a   Teshima, Teruki ^b   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Grade; Prognosis; Prostate carcinoma; Prostate specific antigen; Prostatic neoplasms; Radiation therapy; Radiotherapy; Stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL MODEL; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030824436     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1093::AID-CNCR12>3.0.CO;2-3     Document Type: Article

References (23)

1. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997; 79:2154-61.
2. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995; 13:464-9.
3. Russell KJ, Dunatov C, Hafermann MD. Prostate specificantigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991; 146:1046-52.
4. Zagars G. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23:47-53.
5. Zeitman L, Coen JJ, Shipley WU. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151:640-5.
6. Pisansky TM, Cha SS, Earle JD. Prostate specific-antigen as pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-66.
7. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-4.
8. Roach M, Marquez C, Yuo H-S, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993; 28:33-7.
9. D'Amico A, Propert K. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996; 35(2):273-9.
10. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:293-306.
11. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994; 21:580-97.
12. Hanks GE, Schultheiss TE, Hunt M. Clinical experience with 3D radiotherapy treating prostate cancer. Proceedings of International Symposium on 3D Radiation Treatment of Prostate Cancer, St. Louis, Missouri, April 21-23, 1993.
13. Soffen EM, Hanks GE, Hwang CC, Chu JCH. Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization. Int J Radiat Oncol Biol Phys 1991; 20: 142-6.
14. Marks LS, Treiger B, Dorey FJ, Fu YS, DeKernion JB. Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology 1994; 44:486-92.
15. Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994; 44:199-205.
16. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994; 151:1558-64.
17. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal ultrasound for cancer screening. Radiology 1991; 179:49-53.
18. Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology 1996; 10(8):1143-53.
19. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34:187-220.
20. Collett D. Modeling survival data in medical research. London: Chapman & Hall, 1994.
21. Johnstone PAS, Riffenburgh R, Saunders EL, Willison FW. Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 479-82.
22. Blackwell KI, Bostwick DG, Myers RP, Zincke H, Oesterling JE. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol 1994; 151:1565-70.
23. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996; 36:565-71.